P&T Drug Review Schedule for 2019
P&T Meeting Dates
|
New Reviews |
Re-Reviews
|
April 19, 2019 *
|
|
Angiotensin Modulators
Angiotensin Modulator Combinations
Antihypertensives, Sympatholytic
Beta Blockers
Calcium Channel Blockers
PAH Agents, Oral and Inhaled
Vasodilators, Coronary
Anticoagulants
Platelet Aggregation Inhibitors
Lipotropics, Other
Lipotropics, Statins
Androgenic Agents
BPH Treatments
Bladder Relaxant Preparations
Bone Resorption Suppression and Related Agents
Phosphate Binders
Growth Hormone
Cystic Fibrosis, Oral
Pancreatic Enzymes
Proton Pump Inhibitors
H. Pylori Treatments
GI Motility, Chronic
Ulcerative Colitis Agents
Hepatitis C Agents (Interferons and Ribavirin only)
Multiple Sclerosis Agents
|
May 17, 2019**
|
Antimigraine Agents,
Calcitonin Gene-Related Proteins
|
Hypoglycemics, Metformins
Hypoglycemics, Incretin Mimetics/Enhancers
Hypoglycemics, Insulin
Hypoglycemics, SGLT2
Hypoglycemics, TZD
Hereditary Angioedema Agents
Antivirals, Oral
Antivirals, Topical
Antibiotics, Inhaled
Antibiotics, Topical
Antibiotics, Vaginal
Cephalosporins and Related Agents
Fluroquinolones, Oral
Macrolides
Tetracyclines
Antibiotics, GI
Antifungals, Oral
Antifungals, Topical
Antiparasitics, Topical
Immunosuppressants, Oral
Antimigraine Agents, Triptans
Analgesics, Narcotic long-acting
Analgesics, Narcotic short-acting
Opiate Dependence
Skeletal Muscle Relaxants
Antiemetics/Antivertigo Agents
|
October 18, 2019 ***
|
|
Anti-Allergens, Oral
Antihistamines, Minimally Sedating
Intranasal Rhinitis
Epinephrine, Self-injected
Immunomodulators, Atopic Dermatitis
Immune Globulins
Immunomodulators, Asthma
Bronchodilators, Beta Agonist
Glucocorticoids, Inhaled
Leukotriene Modifiers
COPD Agents
Smoking Cessation
Cytokine/CAM Agents
Botulinum Toxins
Ophthalmic Antibiotics
Ophthalmic Antibiotic/Steroid Combinations
Ophthalmic Antiinflammatories, Immunomodulators
Ophthalmics for Allergic Conjunctivitis
|
November 15, 2019****
|
|
Otic Antibiotics
NSAIDs
Pain, Other
Antipsychotics, Atypical
Antipsychotics, Typical
Antidepressants, Other
Antidepressants, SSRIs
Anticonvulsants
Anxiolytics/Benzodiazepines
Stimulants and Related Agents
Sedative Hypnotics
Alzheimer’s Agents
Antiparkinsons Agents/Restless Leg Syndrome
Movement Disorders
Antihyperurecemics, Oral
Colony Stimulating Factors
Erythropoiesis Stimulating Proteins
|
*The P&T Committee will make its recommendations for these classes immediately following each drug class review. Recommendations will be posted on this Web site by 5 p.m. (MTN Time) on Monday, May 20, 2019. The Department's final PDL decisions for these classes will not be made until financial reviews are done by department staff and PDL decisions approved by the Health and Welfare Director following the May meeting. These final decisions will be effective July 1, 2019.
**The P&T Committee will make its recommendations for these classes immediately following each drug class review. Recommendations will be posted on this Web site by 5 p.m. (MTN Time) on Monday, May 20, 2019. The Department's final PDL decisions for these classes will not be made until financial reviews are done by department staff and PDL decisions approved by the Health and Welfare Director following this meeting. These final decisions will be effective July 1, 2019.
***The P&T Committee will make its recommendations for these classes immediately following each drug class review. Recommendations will be posted on this Web site by 5 p.m. (MTN Time) on Monday, November 18, 2019. The Department's final PDL decisions for these classes will not be made until financial reviews are done by department staff and PDL decisions approved by the Health and Welfare Director following the November meeting. These final decisions will be effective January 6, 2020.
****The P&T Committee will make its recommendations for these classes immediately following each drug class review. Recommendations will be posted on this Web site by 5 p.m. (MTN Time) on Monday, November 18, 2019. The Department's final PDL decisions for these classes will not be made until financial reviews are done by department staff and PDL decisions approved by the Health and Welfare Director following this meeting. These final decisions will be effective January 2, 2020.